PathAI and USZ collaborate to enhance digital pathology with AISight Dx
PathAI announced a partnership with University Hospital Zurich to implement AISight Dx and AIM-TumorCellularity, pioneering AI-driven tumor cell assessment in Swiss pathology labs, improving accuracy and consistency.
PathAI announced a strategic collaboration with University Hospital Zurich (USZ) to deploy AISight Dx, PathAI’s CE-IVD digital pathology platform, together with AIM-TumorCellularity (AIM-TC) to support tumor cell content (TCC) quantification in routine molecular workflows. The collaboration marks one of the first implementations of an AI-based tool in daily pathology operation in Switzerland.
USZ will use AIM-TC to support the routine assessment of TCC prior to next-generation sequencing (NGS), which requires a minimum amount of tumor cells in a sample to allow NGS to accurately detect actionable biomarkers that guide therapy decisions for the patient. The PathAI algorithm provides a stable, quantitative TCC estimate to increase consistency and confidence in the quality of samples selected for molecular diagnostics.
AISight Dx is CE-IVD-marked for primary diagnosis in the EEA, CH, and UK. AIM-TumorCellularity is an AISight Dx workflow tool and not intended to be used for diagnostic purposes.
